Roche reports year-on-year growth in first quarter of 2017

Roche has announced its financial results for the first quarter of 2017, during which it delivered a group sales total of 12.94 billion Swiss francs (10.95 billion pounds).

This represents a year-on-year increase of four percent at constant exchange rates and in Swiss francs, meaning the company remains on course to meet its financial targets for the full year.

Its pharmaceuticals business saw its sales increase by three percent, thanks to strong demand for key brands such as Tecentriq and Perjeta, while diagnostic sales were up by six percent, driven by the strength of its immunodiagnostic solutions market.

Other key milestones achieved during the quarter included the receipt of US regulatory approval for Ocrevus to treat two forms of multiple sclerosis, while Alecensa was approved in the EU for the treatment of a specific form of lung cancer.

For 2017 as a whole, Roche expects sales to grow in the low to mid-single-digit range at constant exchange rates.

Severin Schwan, chief executive officer of Roche, said: "We have started the year with good growth in both our pharmaceuticals and diagnostics divisions and with important positive clinical study results."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.